Calliditas Therapeutics presents data at European Renal Association Congress

Calliditas Therapeutics announced the presentations of an additional efficacy analysis of Nefecon and a real-world analysis of the use of systemic glucocorticoids – SGC – in IgA nephropathy. The presented efficacy analysis of Nefecon and sparsentan showed that treatment with Nefecon for 9 months was associated with estimated glomerular filtration rate benefit compared with continuous treatment with sparsentan. Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids, such as Prednisone and Prednisolone.